The Shift Toward One: Why One Pivotal Study Demands One Essential TMF 

In our recent blog examining the FDA’s move toward a one pivotal trial approval pathway, we explored what this shift means for clinical strategy, regulatory engagement, and evidentiary rigor. As development programs concentrate approval decisions into a single adequate and well-controlled study, the implications extend well beyond protocol design and statistical planning. 

If one study carries the weight of approval, then one record must carry the weight of proof. 

At the center of that record lies the Trial Master File (TMF). 

The Concentration of Risk — and Responsibility 

The movement toward “one” is designed to accelerate access to safe and effective therapies. However, when the evidentiary burden is concentrated into a single pivotal trial, the margin for operational error narrows significantly. 

In a two-trial paradigm, operational deficiencies in one study could sometimes be contextualized by the strength of the other. In a one-trial framework, there is no parallel study to offset documentation gaps, oversight questions, or inconsistencies in execution. 

TMF becomes more than a compliance requirement. It becomes the documentary foundation of substantial evidence. 

Regulators do not approve datasets in isolation. They approve development programs supported by demonstrable compliance, oversight, and traceability. The TMF must show — clearly and contemporaneously — that: 

• The trial was conducted according to the protocol 
• Safety information was distributed appropriately 
• Oversight responsibilities were fulfilled 
• Deviations were identified and managed 
• Vendor performance was supervised 
• Regulatory obligations were met in accordance with local requirements 

When approval hinges on a single pivotal study, the integrity of that documentation becomes inseparable from the integrity of the data itself. 

Inspection Readiness Is No Longer a Phase 

Historically, many organizations treated inspection readiness as a milestone — something to prepare for near database lock or submission. 

That approach is no longer sustainable. 

Under a one-trial model, inspection readiness must be an operational state maintained throughout the lifecycle of the study. TMF must accurately represent study conduct in near real time. Documents should not reconstruct the past; they should reflect it as it unfolds. 

Whether managing 5,000 documents or 75,000, the objective remains the same: alignment between documented evidence, study execution, local regulatory requirements, and defined business practices. 

The question regulators will ask is straightforward: Does the TMF tell a clear and complete story of how this study was conducted? 

If the answer is uncertain, the risk profile of the entire program increases. 

From Administrative Function to Strategic Oversight 

TMF management has evolved beyond document collection. In a one-pivotal-study environment, it becomes a strategic discipline. 

Effective TMF oversight requires teams to evaluate documentation through the lens of an inspector. This means moving beyond checklist-based completeness to assessing: 

• Logical consistency across artifacts 
• Traceability between decisions and documentation 
• Evidence of timely sponsor oversight 
• Alignment between operational actions and filed records 

TMF does not operate in isolation. It is fed by interconnected systems, including clinical trial management systems (CTMS), safety databases, ePRO platforms, and external vendors. 

Increased reliance on confirmatory evidence and integrated development strategies — as discussed in the first blog of this series — amplifies the need for coordination across these systems. Documentation must be reconciled across platforms. Safety letters must demonstrate timely distribution and receipt. Vendor deliverables must reflect active sponsor oversight. 

The TMF is where those relationships become visible. 

The End of Retrospective Reconstruction 

The shift toward one pivotal trial eliminates tolerance for delayed documentation practices. 

Essential vendor records — including oversight documentation and performance assessments — can no longer be assembled at study close. The same holds true for safety documentation. Safety packages must demonstrate timely distribution and acknowledgment by sites, regulatory authorities, and ethics committees in accordance with applicable regulations. 

When documentation is deferred, organizations introduce remediation risk at precisely the moment when regulatory scrutiny intensifies. 

A one-trial approval pathway compresses timelines. That compression leaves little room for large-scale remediation efforts during submission preparation. 

Proactive filing, contemporaneous oversight documentation, and ongoing quality review are no longer best practices. They are prerequisites. 

Holistic Quality Review in a One-Study Model 

Effective TMF quality review demands more than artifact verification. It requires contextual understanding of the development lifecycle. 

Reviewers must be equipped to ask: 

• Does this documentation reflect actual study conduct? 
• Are deviations appropriately documented and reconciled? 
• Do safety communications demonstrate timeliness? 
• Is vendor oversight proportionate and documented? 
• Would an external reviewer understand the sequence of events without additional explanation? 

In a one-pivotal-study framework, the TMF must stand on its own. There is no secondary study to diffuse inspection focus. 

Quality review, therefore, must be continuous and risk-based — not episodic. 

Collaboration as Risk Mitigation 

The first blog in this series emphasized the importance of early regulatory alignment and strategic planning under a one-trial model. That same cross-functional integration must extend into TMF governance. 

Effective remediation and oversight cannot occur in silos. Sponsors, CROs, and vendors must operate with shared visibility and accountability. Regular cross-functional review enables: 

• Earlier identification of documentation gaps 
• Clear ownership of corrective actions 
• Prevention of recurring deficiencies 
• Alignment between operational execution and filed evidence 

When documentation gaps surface late, remediation becomes reactive and disruptive. When oversight is collaborative from the outset, remediation becomes incremental and manageable. 

One Trial, One Record, One Opportunity 

The FDA’s evolving posture toward a single pivotal study framework elevates the importance of precision across the development lifecycle. That precision does not end with statistical design or confirmatory evidence strategy. It extends into the documentary record that supports the study. 

The TMF is no longer simply an archive. It is a living representation of compliance, oversight, and credibility. 

In a one-study approval pathway, there is limited room for reconstruction and limited tolerance for inconsistency. Organizations that treat the TMF as a strategic asset — integrated, continuously reviewed, and aligned with study conduct — will be best positioned to demonstrate quality and withstand regulatory scrutiny. 

As evidentiary models modernize, documentation practices must mature alongside them. 
Because when one trial carries the approval decision, one record must carry the proof. 

The one-trial framework is only one component of a broader regulatory recalibration. In the final installment of this series, we explore five key trends shaping today’s drug development landscape — and what they signal for sponsor strategy moving forward. 

Navigating a one-trial development strategy requires disciplined execution and clear documentation. Premier Research partners with sponsors to strengthen TMF strategy, maintain continuous inspection readiness, and ensure the documentary record reflects the integrity of study conduct. Connect with our team to continue the conversation. 

ABOUT PREMIER RESEARCH:  

Premier Research International LLC (Premier) is a global leader in clinical research and consulting services with expertise in driving an efficient and effective path to market for the life sciences industry. 

Premier is built with the needs of biotech in mind, turning breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value. 

Leveraging deep therapeutic expertise, innovative technology, and product development operational proficiency—from preclinical planning to clinical trial execution and commercialization—our integrated approach offers personalized, end-to-end solutions to identify the pertinent data and insight necessary to make informed decisions earlier and deliver accelerated development timelines for a smarter, faster path to approval. To learn more visit premier-research.com.